2 results
Approved WMOCompleted
Primary ObjectivesTo evaluate the safety and efficacy of 2 fixed doses of EVP-6124 hydrochloride (HCl) ( 2 or 3 mg daily) compared to placebo for 26 weeks in subjects with mild to moderate dementia due to Alzheimer*s disease (AD) currently receiving…
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.